Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?

Immunogenicity, Impact on Carriage and Reactogenicity of 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine in Kenyan Children Aged 1–4 Years: A Randomized Controlled Trial

(2014) Laura L. Hammitt et al.   PLoS One

European enhanced surveillance of invasive pneumococcal disease in 2010: Data from 26 European countries in the post-heptavalent conjugate vaccine era

(2014) Adoración Navarro Torné et al.   VACCINE

The Impact of 7-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease: A Literature Review

(2013) Tin Tin Htar Myint et al.   ADVANCES IN THERAPY

Recommended Adult Immunization Schedule: United States, 2009

(2013)   ANNALS OF INTERNAL MEDICINE

The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe

(2013) M. A. Rose et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Risk factors for community-acquired pneumonia in adults in Europe: a literature review

(2013) Antoni Torres et al.   THORAX

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

(2013) Lisa A. Jackson et al.   VACCINE

Have changing pneumococcal vaccination programmes impacted disease in Ontario?

(2013) Gillian H. Lim et al.   VACCINE

Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: Review of evidence on indirect effects

(2013) Stephanie M. Davis et al.   VACCINE

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

(2013) Lisa A. Jackson et al.   VACCINE

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

(2013) Lisa A. Jackson et al.   VACCINE

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway

(2013) Anneke Steens et al.   VACCINE

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy

(2013) Sara Boccalini et al.   Human Vaccines & Immunotherapeutics

The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England

(2012) Albert Jan van Hoek et al.   JOURNAL OF INFECTION

Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial

(2012) Arto A Palmu et al.   LANCET

Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial

(2011) Alassane Dicko et al.   BMC PUBLIC HEALTH

Long-term protection after immunization with protein–polysaccharide conjugate vaccines in infancy

(2011) Geraldine Blanchard-Rohner et al.   Expert Review of Vaccines

Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeableHaemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) in Mexican infants

(2011) Guillermo M. Ruiz-Palacios et al.   Human vaccines & immunotherapeutics

Alterations in Marginal Zone Macrophages and Marginal Zone B Cells in Old Mice

(2011) S. Z. Birjandi et al.   JOURNAL OF IMMUNOLOGY

Suppressive Effect of Bacterial Polysaccharides on BAFF System Is Responsible for Their Poor Immunogenicity

(2011) S. Kanswal et al.   JOURNAL OF IMMUNOLOGY

Hyporesponsiveness Following Booster Immunization With Bacterial Polysaccharides Is Caused by Apoptosis of Memory B Cells

(2011) Siggeir F. Brynjolfsson et al.   JOURNAL OF INFECTIOUS DISEASES

A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design

(2011) Fikri Y Avci et al.   NATURE MEDICINE

Immunogenicity, Safety, and Reactogenicity of the 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine and DTPa-IPV-Hib When Coadministered as a 3-dose Primary Vaccination Schedule in the Netherlands

(2011) Menno R. van den Bergh et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

IL-21 induces death of marginal zone B cells during chronic inflammation

(2010) L. Tortola et al.   BLOOD

Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland

(2010) M. Patrzałek et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe

(2010) Ralf R Reinert et al.   Expert Review of Vaccines

The Spectrum of Invasive Pneumococcal Disease at an Adult Tertiary Care Hospital in the Early 21st Century

(2010) Adriana M. Rueda et al.   MEDICINE

A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults

(2010) Neil French et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vaccinations in patients with immune-mediated inflammatory diseases

(2010) J.-F. Rahier et al.   RHEUMATOLOGY

Clinical and economic burden of community-acquired pneumonia among adults in Europe

(2010) T Welte et al.   THORAX

The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003–2007)

(2010) Ruth Gil-Prieto et al.   VACCINE

The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells

(2009) M. Taillardet et al.   BLOOD

Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine

(2009) E. Pérez-Trallero et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines

(2009) Daniel J. Isaacman et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

(2009) Katherine L O'Brien et al.   LANCET

The 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Coadministered With DTPw-HBV/Hib and Poliovirus Vaccines: Assessment of Immunogenicity

(2009) Nancy Bermal et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the Licensed 7vCRM Vaccine

(2009) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits

(2009) Angelique G.S.C. Jansen et al.   VACCINE

Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany

(2009) Simon Rückinger et al.   VACCINE

Impact of Heptavalent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage of Penicillin-Resistant Streptococcus pneumoniae Among Day-Care Center Attendees in Central Greece

(2008) Ioanna N. Grivea et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Trends in Acute Otitis Media-Related Health Care Utilization by Privately Insured Young Children in the United States, 1997-2004

(2008) F. Zhou et al.   PEDIATRICS

Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway

(2008) Didrik F. Vestrheim et al.   VACCINE